Research Catalog

Research peptides, small molecules, and laboratory supplies for in vitro research. Every lot is HPLC/MS-verified for identity and purity.

90 products found

Sort by:

99.4% Purity

In Stock

SKU CAG5-TIRZ10-BLD

Cagrilintide (5mg) / Tirz (10mg)

Triple-Receptor Agonist: Combines amylin, GIP, and GLP-1 pathways in one formulation
Multi-Pathway Engagement: Three independent satiety and metabolic control mechanisms
Research Blend: 5mg Cagrilintide + 10mg Tirzepatide, ≥98% purity each component

99.4% Purity

In Stock

SKU RC-THYMOSIN-ALPHA-1-10M

Thymosin Alpha-1

28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction

99.4% Purity

In Stock

SKU RC-TESOFENSINE-CAPSULES

Tesofensine Capsules (500mcg) 100 Count

Triple monoamine reuptake inhibitor (TRI) potently inhibiting presynaptic reuptake of serotonin, norepinephrine, and dopamine with IC₅₀ values: NET 1.7-3.2 nM, SERT 11 nM, DAT 8.0-65 nM
Produces approximately twice the weight loss of currently marketed anti-obesity medications; Phase II trials: 9-11% body weight reduction over 24 weeks at therapeutic doses (0.5-1.0 mg)
FDA orphan drug designation for Tesomet (tesofensine + metoprolol) in Prader-Willi syndrome (March 2021) and hypothalamic obesity (July 2021); exceptionally long half-life (~9 days) enabling once-daily dosing

99.4% Purity

In Stock

SKU RC-TB-500-5MG

TB-500 (Thymosin Beta-4) (43aa)

Thymosin Beta-4 Derivative: 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH), derived from naturally occurring thymosin beta-4 (70-80% of beta-thymosins), 2,000+ publications, N-terminal acetylation for enhanced stability
Multi-Pathway Regeneration: G-actin sequestration (Kd 0.5-0.7 μM), cell migration promotion, VEGF upregulation via Wnt/β-catenin/Lef-1, angiogenesis, PI3K/Akt/eNOS survival pathway, anti-fibrotic via TGF-β1 suppression
Clinical Status: No FDA-approved human drug, all therapeutic data preclinical (wound healing, cardiac repair, pulmonary fibrosis, Alzheimer's neuroprotection), extensive safety profile in animal models

99.4% Purity

In Stock

SKU RC-SNAP-8-10MG

SNAP-8 (10mg)

SNAP-8 (Acetyl Octapeptide-3) is an 8-amino acid biomimetic peptide (Ac-EEMQRRAD-NH2) that competitively inhibits SNAP-25 incorporation into the SNARE complex, achieving ~43% inhibition of glutamate release
Developed as a topical alternative to botulinum toxin, it provides muscle relaxation (not paralysis) with reversible, dose-dependent modulation of neurotransmitter release

99.4% Purity

In Stock

SKU RC-SLU-PP-332-CAPSULES-

SLU-PP-332 Capsules (250mcg) 100 Count

Pan-ERR Agonist Exercise Mimetic: Hydrazone small molecule (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide, Saint Louis University design, activates ERRalpha/beta/gamma (EC50 98/230/430 nM), 10+ publications, all preclinical
Multi-System Metabolic Reprogramming: 70% increased endurance, 12% body weight loss, mitochondrial biogenesis via PGC-1alpha/AMPK/TFAM cascade, type IIa muscle fiber conversion, 25% increased fatty acid oxidation, reverses age-related kidney dysfunction
Clinical Status: No human trials (as of Feb 2026), all data from mouse models, well-tolerated in 8-week studies, successor compound SLU-PP-915 with improved oral bioavailability developed 2026

99.4% Purity

In Stock

SKU RC-SEMAX-10MG

Semax 30mg

ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile

99.4% Purity

In Stock

SKU RC-SEMAGLUTIDE-CAPSULES

Semaglutide Capsules (500mcg) 25 Count

Oral semaglutide is a 31-amino acid GLP-1 receptor agonist with engineered modifications (Aib8, C-18 fatty di-acid, Lys34Arg) enabling oral bioavailability via SNAC absorption enhancement technology
Research demonstrates glycemic control comparable to injectable GLP-1 agonists with 15
1% weight loss (50mg dose, OASIS-1 trial)

99.4% Purity

In Stock

SKU RC-VIAL-STORAGE

Vial Storage

Profile: Vial storage container for research peptides
Quality: >=95% Purity (HPLC Verified)

99.4% Purity

In Stock

SKU RC-SELANK-SELANK-10MG

Selank 10mg

Synthetic Tuftsin Analogue: Heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed Russian Academy of Sciences, tuftsin core + Pro-Gly-Pro extension for metabolic stability, 20+ years research
Multi-Modal Mechanism: Positive allosteric modulator of GABA-A receptors, upregulates BDNF (hippocampus/cortex), inhibits enkephalinase (IC50 15 μM), modulates monoamines, no tolerance/dependence
Clinical Status: Russian FDA approved 2009 for GAD/neurasthenia (intranasal 0.15%), RCT showed efficacy equal to medazepam with additional nootropic effects, no sedation/amnesia unlike benzodiazepines

99.4% Purity

In Stock

SKU RC-RECONSTITUTION-SOLUT

Reconstitution Solution (10ml)

Profile: Sterile bacteriostatic water for peptide reconstitution
Quality: >=95% Purity (HPLC Verified)

99.4% Purity

In Stock

SKU RC-RAD140-CAPSULES-15MG

Rad140 Capsules (15mg) 60 Count

Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use